1-3 of 3
Hélène Asnagli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Christina Pfeiffer, Alexander Michael Grandits, Hélène Asnagli, Anja Schneller, Julia Huber, Niklas Zojer, Martin Schreder, Andrew Parker, Arnold Bolomsky, Philip Beer, Heinz Ludwig
Journal: Blood
Blood (2022) 140 (Supplement 1): 7088–7089.
https://doi.org/10.1182/blood-2022-160333
Published: 2022
Journal Articles

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

David Chiron, Emmanuelle Menoret, Charlotte Kervoelen, Sophie Maïga, Celine Bellanger, Benoit Tessoulin, Cyrille Touzeau, Hélène Asnagli, Andy Parker, Philip Beer, Catherine Pellat-Deceunynck
Journal: Blood
Blood (2022) 140 (Supplement 1): 6014–6015.
https://doi.org/10.1182/blood-2022-159449
Published: 2022
Journal Articles

A Phase 1/2 Study of STP938, a First in Class Inhibitor of CTP Synthase 1, in Patients with Relapsed/Refractory B or T Cell Lymphoma

Philip Beer, Maureen Higgins, Hélène Asnagli, Eef Hoeben, Michael Hubank, Andrew Parker, Brian Schwartz
Journal: Blood
Blood (2022) 140 (Supplement 1): 12027–12028.
https://doi.org/10.1182/blood-2022-159963
Published: 2022